A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-845

  • End date
    Dec 25, 2021
  • participants needed
  • sponsor
    Chong Kun Dang Pharmaceutical
Updated on 27 January 2021


A clinical trial to evaluate the pharmacokinetic profiles and safety of CKD-845.


A phase 1 clinical trial to evaluate pharmacokinetics and safety in male after administration of CKD-845 and D309.

Condition Hypogonadism
Treatment D309, CKD-845
Clinical Study IdentifierNCT04673682
SponsorChong Kun Dang Pharmaceutical
Last Modified on27 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 19 yrs and 65 yrs?
Are you male?
Do you have any of these conditions: Do you have Hypogonadism??
Adult Male over 19 years old and under 65 years old at screening
Serum total testosterone level under 3.0 ng/mL at screening
Subjects who had 18.5 kg/m2 Body Mass Index(BMI) < 30.5 kg/m2 and a total body weight 55 kg
Body Mass Index(BMI) = Weight(kg) / [Height(m)]2
Subjects without congenital/chronic diseases and without abnormal symptoms or diagnosis based on a medical examination within the last 3 years, except for hypogonadism
Subjects who were deemed to be appropriate as study subjects in accordance with the screening results (laboratory tests, vital signs, ECG etc.)
Subjects who voluntarily signed an informed consent form approved by the Institutional Review Board(IRB) of each clinical study site and decided to participate in the study after being fully informed of the study prior to participation, including the objective, content of the clinical trial
Subjects who consent to the use of reliable contraception during the clinical trial. Subjects who have no plan of pregnancy and agree to not donate his sperm during the study period and up until 180 days after the last administration of investigational product
Subjects with the ability and willingness to participate during the study period

Exclusion Criteria

Subjects with a medical evidence or a history (excluding a hypogonadism, dental history of periodontal surgery, impacted wisdom teeth removal, etc.) of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurologic or immune disease
-1. Subjects with a severe acute/chronic physical and mental conditions that
can increase risk or interfere with the interpretation of the results of test
-2. Subjects who have a androgen-dependent tumor(e.g., prostate cancer, male
breast cancer)
-3. Subjects with hypercalcemia associated with malignant tumors
-4. Subjects with or with a history of liver tumors
-5. Subjects with bone metastasis of cancer
-6. Subjects being treated for an enlarged prostate
-7. Subjects who have severe alcohol and/or drug abuse history within a year
from screening
-8. Insulin-dependent diabetes mellitus or uncontrolled non-insulin-
dependent diabetes mellitus
\. Subjects with the following laboratory test results at screening
-1. AST, ALT exceeding 2.5 times from the upper limit of normal
-2. Total bilirubin exceeding 2.5 times from the upper limit of normal
-3. Subjects had renal impairment(eGFR < 60 mL/min/1.73 m2)
-4. Positive results of virus/bacterial test and/or urine drug test at
-5. Systolic blood pressure >150 mmHg or <90 mmHg and/or diastolic blood
pressure >60 mmHg or >95 mmHg at sitting position
\. History of regular alcohol consumption exceeding 210 g/week within 6
months prior to screening (1 drink (250 mL) of beer (5%) = 10 g, 1 drink (50
mL) of hard liquor (20%)
g; 1 drink (125 mL of wine (12%) = 12 g). 4. Subjects who smoked more than 20 cigarettes per day within 6 months prior to screening. 5. Subjects who had been administered investigational product(s) from other clinical study or bioequivalence study within 180 days prior to the first dose of this study(except when subject have not taken investigational product(s)). 6. Subjects who had taken any drug(s) known as a strong inducer(s) or inhibitor(s) of drug-metabolizing enzymes within 30 days prior to the first dose of investigational product(s). 7. Subjects who had taken any contraindication drug(s)(Drug influencing the level of serum testosterone, modulating activity of testosterone and which have drug interaction) within 28 days prior to the first dose of investigational product(s). 8. Subjects who use of oral anticoagulants (with the exception of low-dose aspirin) within 28 days prior to the first dose of investigational product(s). 9. Subjects who use the testosterone pellet within 90 days prior to the first dose of investigational product(s). 10. Subjects who use of any injectable testosterone preparations within 28 days prior to the first dose of investigational product(s). 11. Subjects who use oral testosterone products within 7 days prior to the first dose of investigational product(s). 12. Subjects who use of supplements (e.g., saw palmetto, phytoestrogen, androstenedione, DHEA, niacin, fish oil etc.) prior to the first dose of investigational product(s). 13. Subjects who have hypersensitivity of investigational products and its components. 14. Subjects who donated whole blood within 60 days or blood components within 30 days prior to the first dose of the investigational product(s). 15. Subjects who were deemed inappropriate to participate in the study by the investigator
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note